A validated disease severity scoring system for Fabry disease

Molecular Genetics and Metabolism

Volumn 99, Issue 3, 2010, Pages 283-290

  Giannini, Edward H ^a   Mehta, Atul B ^b   Hilz, Max J ^c,d   Beck, Michael ^e   Bichet, Daniel G ^f   Brady, Roscoe O ^g   West, Michael ^h   Germain, Dominique P ⁱ   Wanner, Christoph ^j   Waldek, Stephen ^k   Clarke, Joe T R ^l,m   Mengel, Eugen ^e   Strotmann, Jörg M ^j   Warnock, David G ⁿ   Linhart, Ales ^o  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d NEW YORK UNIVERSITY   (United States)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^g NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^l HOSPITAL FOR SICK CHILDREN   (Canada)

^m UNIVERSITY OF SHERBROOKE   (Canada)

ⁿ University of Alabama at Birmingham   (United States)

^o CHARLES UNIVERSITY   (Czech Republic)

more..

Author keywords

Galactosidase A; DS3; Fabry disease; Inherited metabolic disorder; Severity scoring

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CONSENSUS; CONTENT VALIDITY; DISEASE COURSE; DISEASE SEVERITY; FABRY DISEASE; HUMAN; PRIORITY JOURNAL; RELIABILITY; SCORING SYSTEM;

ACTIVITIES OF DAILY LIVING; ALPHA-GALACTOSIDASE; DISEASE PROGRESSION; FABRY DISEASE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PAIN MEASUREMENT; PHENOTYPE; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 76549116109     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.10.178     Document Type: Article

References (39)

1. Brady R.O., Gal A.E., Bradley R.M., Martensson E., Warshaw A.L., and Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N. Engl. J. Med. 276 (1967) 1163-1167
2. R.J. Desnick, Y.A. Ioannou, C.M. Eng, α-Galactosidase A deficiency Fabry disease, in: C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease, eighth ed., vol. 3, McGraw-Hill, New York, 2001, pp. 3733-3774.
3. Branton M.H., Schiffmann R., Sabnis S.G., Murray G.J., Quirk J.M., Altarescu G., Goldfarb L., Brady R.O., Balow J.E., Austin Iii H.A., and Kopp J.B. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 81 (2002) 122-138
4. Deegan P.B., Baehner A.F., Barba Romero M.A., Hughes D.A., Kampmann C., and Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J. Med. Genet. 43 (2006) 347-352
5. Ortiz A., Oliveira J.P., Waldek S., Warnock D.G., Cianciaruso B., and Wanner C. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol. Dial. Transplant. 23 (2008) 1600-1607
6. Wang R.Y., Lelis A., Mirocha J., and Wilcox W.R. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med. 9 (2007) 34-45
7. Wilcox W.R., Oliveira J.P., Hopkin R.J., Ortiz A., Banikazemi M., Feldt-Rasmussen U., Sims K., Waldek S., Pastores G.M., Lee P., Eng C.M., Marodi L., Stanford K.E., Breunig F., Wanner C., Warnock D.G., Lemay R.M., and Germain D.P. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol. Genet. Metab. 93 (2007) 112-128
8. Meikle P.J., Hopwood J.J., Clague A.E., and Carey W.F. Prevalence of lysosomal storage disorders. JAMA 281 (1999) 249-254
9. Spada M., Pagliardini S., Yasuda M., Tukel T., Thiagarajan G., Sakuraba H., Ponzone A., and Desnick R.J. High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Genet. 79 (2006) 31-40
10. Hopkin R.J., Bissler J., Banikazemi M., Clarke L., Eng C.M., Germain D.P., Lemay R., Tylki-Szymanska A., and Wilcox W.R. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr. Res. 64 (2008) 550-555
11. Ramaswami U., Whybra C., Parini R., Pintos-Morell G., Mehta A., Sunder-Plassmann G., Widmer U., and Beck M. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 95 (2006) 86-92
12. Schiffmann R., Warnock D.G., Banikazemi M., Bultas J., Linthorst G.E., Packman S., Sorensen S.A., Wilcox W.R., and Desnick R.J. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol. Dial. Transplant. 24 (2009) 2102-2111
13. Linhart A., Kampmann C., Zamorano J.L., Sunder-Plassmann G., Beck M., Mehta A., and Elliott P.M. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur. Heart J. 28 (2007) 1228-1235
14. Sims K., Politei J., Banikazemi M., and Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Natural history data from the Fabry Registry. Stroke 40 (2009) 788-794
15. Germain D.P., Avan P., Chassaing A., and Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med. Genet. 3 (2002) 10
16. Crutchfield K.E., Patronas N.J., Dambrosia J.M., Frei K.P., Banerjee T.K., Barton N.W., and Schiffmann R. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50 (1998) 1746-1749
17. Fellgiebel A., Keller I., Marin D., Muller M.J., Schermuly I., Yakushev I., Albrecht J., Bellhauser H., Kinateder M., Beck M., and Stoeter P. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 72 (2009) 63-68
18. Mayes J.S., Scheerer J.B., Sifers R.N., and Donaldson M.L. Differential assay for lysosomal α-galactosidases in human tissues and its application to Fabry's disease. Clin. Chim. Acta 112 (1981) 247-251
19. Linthorst G.E., Vedder A.C., Aerts J.M., and Hollak C.E. Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin. Chim. Acta 353 (2005) 201-203
20. Eng C.M., Germain D.P., Banikazemi M., Warnock D.G., Wanner C., Hopkin R.J., Bultas J., Lee P., Sims K., Brodie S.E., Pastores G.M., Strotmann J.M., and Wilcox W.R. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet. Med. 8 (2006) 539-548
21. Germain D.P., Waldek S., Banikazemi M., Bushinsky D.A., Charrow J., Desnick R.J., Lee P., Loew T., Vedder A.C., Abichandani R., Wilcox W.R., and Guffon N. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J. Am. Soc. Nephrol. 18 (2007) 1547-1557
22. Schiffmann R., Ries M., Timmons M., Flaherty J.T., and Brady R.O. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol. Dial. Transplant. 21 (2006) 345-354
23. Desnick R.J., Brady R.O., Barranger J., Collins A.J., Germain D.P., Goldman M., Grabowski G., Packman S., and Wilcox W.R. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann. Intern. Med. 138 (2003) 338-346
24. A.L. Delbecq, A.H. van de Ven, D.H. Gustafson, Guidelines for conducting nominal group technique meetings, in: A.L. Delbecq, A.H. van de Ven, D.H. Gustafson (Eds.), Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes, Greenbriar Press, Middleton, WI, 1986.
25. Bombardier C., and Tugwell P. A methodological framework to develop and select indices for clinical trials: statistical and judgmental approaches. J. Rheumatol. 9 (1982) 753-757
26. W. Guy, Clinical global impression (CGI), in: ECDEU Assessment Manual for Psychopharmacology, National Institute of Mental Health, Rockville, MD, 1976, pp. 218-222.
27. Huber C.G., Lambert M., Naber D., Schacht A., Hundemer H.P., Wagner T.T., and Schimmelmann B.G. Validation of a Clinical Global Impression Scale for Aggression (CGI-A) in a sample of 558 psychiatric patients. Schizophr. Res. 100 (2008) 342-348
28. Schneider L.S., and Olin J.T. Clinical global impressions in Alzheimer's clinical trials. Int. Psychogeriatr. 8 (1996) 277-288
29. Davies E.H., Surtees R., DeVile C., Schoon I., and Vellodi A. A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J. Inherit. Metab. Dis. 30 (2007) 768-782
30. Beaton D.E., Bombardier C., Katz J.N., and Wright J.G. A taxonomy for responsiveness. J. Clin. Epidemiol. 54 (2001) 1204-1217
31. Viera A.J., and Garrett J.M. Understanding interobserver agreement: the kappa statistic. Fam. Med. 37 (2005) 360-363
32. Schafer J.L., and Graham J.W. Missing data: our view of the state of the art. Psychol. Methods 7 (2002) 147-177
33. Aerts J.M., Groener J.E., Kuiper S., Donker-Koopman W.E., Strijland A., Ottenhoff R., van Roomen C., Mirzaian M., Wijburg F.A., Linthorst G.E., Vedder A.C., Rombach S.M., Cox-Brinkman J., Somerharju P., Boot R.G., Hollak C.E., Brady R.O., and Poorthuis B.J. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl. Acad. Sci. USA 105 (2008) 2812-2817
34. Cox T.M. Biomarkers in lysosomal storage diseases: a review. Acta Paediatr. 94 Suppl. (2005) 39-42
35. Mills K., Morris P., Lee P., Vellodi A., Waldek S., Young E., and Winchester B. Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. J. Inherit. Metab. Dis. 28 (2005) 35-48
36. Young E., Mills K., Morris P., Vellodi A., Lee P., Waldek S., and Winchester B. Is globotriaosylceramide a useful biomarker in Fabry disease?. Acta Paediatr. 94 Suppl. (2005) 51-54
37. Zarate Y.A., and Hopkin R.J. Fabry's disease. Lancet 372 (2008) 1427-1435
38. U.S. Food and Drug Administration, Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance, 2006. Available from: (accessed 18.06.09).
39. Whybra C., Kampmann C., Krummenauer F., Ries M., Mengel E., Miebach E., Baehner F., Kim K., Bajbouj M., Schwarting A., Gal A., and Beck M. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin. Genet. 65 (2004) 299-307